March 14 (Reuters) - AstraZeneca Plc on Sunday said
it had conducted a review of people vaccinated with its COVID-19
vaccine which has shown no evidence of an increased risk of
blood clots.
The review covered more than 17 million people vaccinated in
the European Union and United Kingdom.
"A careful review of all available safety data of more than
17 million people vaccinated in the European Union and UK with
COVID-19 Vaccine AstraZeneca has shown no evidence of an
increased risk of pulmonary embolism, deep vein thrombosis or
thrombocytopenia, in any defined age group, gender, batch or in
any particular country," the statement said.
(Reporting by Radhika Anilkumar in Bengaluru. Editing by Jane
Merriman)